References

Cancer statistics, 2025

2025 · External reference

EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent

10.1016/j.eururo.2024.03.027 · 2024 · External reference

Differing recommendations on prostate biopsy approach to minimize infections: an examination of the european association of urology and American urological association guidelines

10.1016/j.eururo.2023.05.036 · 2023 · External reference

Effectiveness of intrarectal povidone-iodine cleansing plus formalin disinfection of the needle tip in decreasing infectious complications after transrectal prostate biopsy: a randomized controlled trial

10.1097/ju.0000000000002910 · 2022 · External reference

The effect of different types of prostate biopsy techniques on post-biopsy infectious complications

10.1097/ju.0000000000002497 · 2022 · External reference

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication

10.1200/jco.2009.24.1968 · 2010 · External reference

Trends in the use of liquid biopsy in oncology

10.1038/d41573-023-00111-y · 2023 · External reference

Liquid biopsy epigenomic profiling for cancer subtyping

10.1038/s41591-023-02605-z · 2023 · External reference

The role of circulating tumor cells as a liquid biopsy for cancer: advances, biology, technical challenges, and clinical relevance

10.3390/cancers16071377 · 2024 · External reference

Biomarkers for pre-treatment risk stratification of prostate cancer patients: a systematic review

10.3390/cancers16071363 · 2024 · External reference

Liquid biopsy testing in urological cancers: focus on urine

10.1016/j.urolonc.2025.07.034 · 2025 · External reference

Blood and urine-based biomarkers in prostate cancer: current advances, clinical applications, and future directions

10.1016/j.jlb.2025.100305 · 2025 · External reference

MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies

10.1038/s12276-023-01050-9 · 2023 · External reference

The role of miRNA in prostate cancer diagnosis, prognosis and treatment response: a narrative review

10.2217/fon-2022-0891 · 2023 · External reference

Implications of human genetic variation in CRISPR-based therapeutic genome editing

10.1038/nm.4377 · 2017 · External reference

CRISPR-based diagnostics

10.1038/s41551-021-00760-7 · 2021 · External reference

PddCas: a polydisperse droplet digital CRISPR/Cas-Based assay for the rapid and ultrasensitive amplification-free detection of viral DNA/RNA

2023 · External reference

Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial

10.1016/j.eururo.2023.12.015 · 2024 · External reference

Stard 2015: an updated list of essential items for reporting diagnostic accuracy studies

2015 · External reference

Prostate biopsy: when and how to perform

10.1016/j.crad.2019.03.016 · 2019 · External reference

Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer

10.1158/1078-0432.ccr-18-2849 · 2019 · External reference

Nanoarchitectonics-assisted simultaneous fluorescence detection of urinary dual miRNAs for noninvasive diagnosis of prostate cancer

10.1021/acs.analchem.3c00701 · 2023 · External reference

Urinary microRNAs and their significance in prostate cancer diagnosis: a 5-Year update

10.3390/cancers14133157 · 2022 · External reference

MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer

2021 · External reference

A plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer

10.1038/s41598-018-24424-w · 2018 · External reference

Liquid biomarkers in prostate cancer diagnosis: current status and emerging prospects

10.5534/wjmh.230386 · 2025 · External reference

Prostate cancer risk biomarkers from large cohort and prospective metabolomics studies: a systematic review

10.1016/j.tranon.2024.102196 · 2025 · External reference

Performance of 4Kscore as a reflex test to prostate-specific antigen in the GÖTEBORG-2 prostate cancer screening trial

10.1016/j.eururo.2024.04.037 · 2024 · External reference

Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study

10.1093/jnci/djv095 · 2015 · External reference

A multicentre evaluation of the role of the prostate health index (PHI) in regions with differing prevalence of prostate cancer: adjustment of PHI reference ranges is needed for European and Asian settings

10.1016/j.eururo.2018.10.047 · 2019 · External reference

Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy

10.1016/j.juro.2013.12.005 · 2014 · External reference

Mechanistic insights and molecular diagnostics of TMPRSS2-ERG: overview of the journey from regulation of signaling landscape in fusion positive prostate cancer to appraisal as a diagnostic marker

10.31083/j.fbl2910343 · 2024 · External reference

Gene set enrichment analysis: performance evaluation and usage guidelines

10.1093/bib/bbr049 · 2012 · External reference